Enliven Therapeutics, Inc.
NASDAQ:ELVN · NASDAQ Global Select
-$0.12 today
Vol 2.16M · Avg 1.35M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-22.6%
avg 1.6%
ROIC
-26.0%
avg -49.4%
ROA
-21.8%
avg -42.3%
Analysis
ROA is currently the strongest return metric at -21.8% versus its period average of -42.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Samuel S. Kintz | Co-Founder & Head of Pipeline | $956,094.00 | — | 40 | $890,392.00 | 1.46% |
Helen Louise Collins | Chief Medical Officer | $726,420.00 | — | 63 | $25,000.00 | 0.04% |
Joseph Lyssikatos | Co-Founder & Research Fellow | $709,400.00 | — | 61 | $112,500.00 | 0.18% |
Richard A. Fair | CEO, President & Director | $672,656.00 | — | 57 | $22,647.00 | 0.04% |
Benjamin Hohl | Chief Financial Officer & Head of Corporate Development | $667,894.00 | — | 37 | $51,000.00 | 0.08% |
Anish Patel | Co-Founder & Chief Operating Officer | — | — | 45 | $120,000.00 | 0.20% |
Galya D. Blachman | Chief Legal Officer & Head of Business Development | — | — | 49 | $17,126.00 | 0.03% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
73
$27.39M
Net Sentiment
$27.39M
Net selling
Most Active
Lyssikatos Joseph P
19 transactions
1–10 of 73
Analysis
Insiders reported 0 buys worth $0.00 and 73 sells worth $27.39M over the last 12 months. That adds up to net selling of $27.39M. Lyssikatos Joseph P was the most active insider with 19 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector

Dianthus Therapeutics, Inc.
NASDAQ:DNTH
$3.36B

Relay Therapeutics, Inc.
NASDAQ:RLAY
$2.80B

Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.71B

Atai Beckley Inc.
NASDAQ:ATAI
$1.47B

Precigen, Inc.
NASDAQ:PGEN
$1.42B

Inhibrx Biosciences, Inc.
NASDAQ:INBX
$1.36B

Immatics N.V.
NASDAQ:IMTX
$1.31B

Nektar Therapeutics
NASDAQ:NKTR
$1.18B

ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$882.49M

Sana Biotechnology, Inc.
NASDAQ:SANA
$854.36M
Who manages ELVN?
Enliven Therapeutics, Inc. (ELVN) lists 7 active executives. The top listed executive is Samuel S. Kintz, Co-Founder & Head of Pipeline.
Are ELVN insiders buying or selling?
Recent insider activity shows net buying of $33.54M.
Explore More
Continue the stock analysis
Jump to another research area for this company.